ProfileGDS5678 / 1455270_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 17% 18% 17% 18% 18% 18% 18% 18% 30% 18% 18% 18% 18% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4464417
GSM967853U87-EV human glioblastoma xenograft - Control 22.4406118
GSM967854U87-EV human glioblastoma xenograft - Control 32.4261317
GSM967855U87-EV human glioblastoma xenograft - Control 42.3789318
GSM967856U87-EV human glioblastoma xenograft - Control 52.379318
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4867918
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4649518
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4225618
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6604430
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4355918
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4173118
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4042118
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4309518
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4409519